Results 241 to 250 of about 138,770 (367)
A comprehensive review on computational metabolomics: Advancing multiscale analysis through <i>in-silico</i> approaches. [PDF]
Nafie MS, Abu-Elsaoud AM, Diab MK.
europepmc +1 more source
Differential regulation of the CDK inhibitor p27 (KIP1) following CCL4 induced liver injury
Angela L. Tyner+3 more
openalex +1 more source
CDK Inhibitor p18INK4c Is Required for the Generation of Functional Plasma Cells [PDF]
Michelle R. Tourigny+11 more
openalex +1 more source
Cell cycle, cytoskeleton dynamics and beyond: the many functions of cyclins and CDK inhibitors
N. Bendris, B. Lemmers, J. Blanchard
semanticscholar +1 more source
Cellular Senescence in Cancer: Mechanisms, Roles in Tumor Progression, and Therapeutic Implications
Senescent tumor cells in TME exhibit dual roles. “Angels” secrete SASPs/DAMPs to boost immunological clearance and antitumor immunity via MHC‐I upregulation; “Demons” produce tumor‐promoting SASPs recruiting MDSCs to drive malignancy. ABSTRACT Cellular senescence, a state of irreversible cell cycle arrest accompanied by a senescence‐associated ...
Jingrui Yan+5 more
wiley +1 more source
Summary Developmental processes are regulated at multiple levels, including the epigenetic level. Among the epigenetic factors, histone H3 lysine 4 (H3K4) methyltransferases contribute to active transcription of target genes, and here, we explored how the H3K4 methyltransferase ARABIDOPSIS HOMOLOG OF TRITHORAX1 (ATX1) affects Arabidopsis thaliana ...
Selene Napsucialy‐Mendivil+7 more
wiley +1 more source
Hallmarks and mechanisms of cellular senescence in aging and disease. [PDF]
Ajoolabady A+6 more
europepmc +1 more source
The Proto-oncogene c-myc Acts through the Cyclin-dependent Kinase (Cdk) Inhibitor p27Kip1to Facilitate the Activation of Cdk4/6 and Early G1Phase Progression [PDF]
Álvaro J. Obaya+3 more
openalex +1 more source
This study investigates an alternative approach to reactivating the oncosuppressor p53 in cancer. A short peptide targeting the association of the two p53 inhibitors, MDM2 and MDM4, induces an otherwise therapeutically active p53 with unique features that promote cell death and potentially reduce toxicity towards proliferating nontumor cells.
Sonia Valentini+10 more
wiley +1 more source